爱尚大众

Wuhan Dazhong Dental Medical Co., Ltd.

武漢大眾口腔醫療股份有限公司

(A joint stock company with limited liability incorporated in the People's Republic of China)

(Stock Code: 2651)

ANNOUNCEMENT
(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 24, 2025
(2) CANCELLATION OF THE BOARD OF SUPERVISORS AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
(3) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR
(4) ADJUSTMENT OF MEMBERS OF COMMITTEES UNDER THE BOARD AND
(5) ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR

References are made to the notice and the circular dated October 8, 2025 (the "**Circular**") of the extraordinary general meeting (the "**EGM**") of Wuhan Dazhong Dental Medical Co., Ltd. (the "**Company**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that the EGM was convened at No. 8 Conference Room, 11/F, Huayin Building, No. 786 Minzhu Road, Zhongnan Road Sub-District, Wuchang District, Wuhan, Hubei Province, People's Republic of China ("**PRC**") at 9:00 a.m. on Friday, October 24, 2025.

As at the date of the EGM, the number of issued Shares of the Company was 49,379,042, comprising 32,352,902 Unlisted Shares and 17,026,140 H Shares. The Company did not hold any treasury shares (including any treasury shares held or deposited in the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited). No Shareholder was required to abstain from voting on any resolution at the EGM pursuant to the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Accordingly, the total number of Shares entitled to attend and vote on the resolutions proposed at the EGM was 49,379,042.

No Shareholder was entitled to attend the EGM but required to abstain from voting in favor of the resolutions pursuant to Rule 13.40 of the Listing Rules. No Shareholder indicated in the Circular an intention to vote against the resolutions or to abstain from voting at the EGM.

Shareholders or proxies of Shareholders present at the EGM held 41,197,242 Shares in aggregate.

The executive Directors of the Company, Mr. Yao Xue, Ms. Shen Hongmin, Mr. Guo Jiaping and Ms. Liu Hongchan, and the independent non-executive Directors of the Company, Mr. Shu Yijie, Ms. Huang Suzhen and Ms. Wang Taosha, were present at the EGM.

The Company's H Share Registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the EGM. The Supervisors and Shareholder representatives of the Company were also responsible for scrutinizing and vote-taking at the EGM. All resolutions were voted by way of poll and approved by Shareholders.

The poll results for resolutions proposed at the EGM are detailed as follows:

Special Resolution		**Number of votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the resolution in relation to the cancellation of the Board of Supervisors and amendments to the Articles of Association of the Company.	41,197,242 (100.0000%)	0 (0.0000%)	0 (0.0000%)
Ordinary Resolutions		**Number of votes(%)**		
		For	**Against**	**Abstain**
2.	To consider and approve the resolution in relation to amendments to the Rules of Procedure of the Shareholders' General Meeting of the Company.	41,197,242 (100.0000%)	0 (0.0000%)	0 (0.0000%)
3.	To consider and approve the resolution in relation to amendments to the Rules of Procedure of the Board of Directors of the Company.	41,197,242 (100.0000%)	0 (0.0000%)	0 (0.0000%)
4.	To consider and approve the resolution in relation to the authorization to the Board and/or its authorized persons to have full authority to review and consider the content related to the Board of Supervisors or Supervisors in other rules and regulations of the Company and make appropriate amendments accordingly.	41,197,242 (100.0000%)	0 (0.0000%)	0 (0.0000%)
5.	To consider and approve the resolution in relation to the appointment of Mr. Xie Dong as an independent non-executive Director.	41,197,242 (100.0000%)	0 (0.0000%)	0 (0.0000%)

The above-mentioned special resolution No. 1 was duly passed with more than two-thirds of the votes cast in favor; the above-mentioned ordinary resolutions No. 2 to No. 5 were duly passed with more than half of the votes cast in favor. No new proposal was submitted for voting and approval at the EGM.

CANCELLATION OF THE BOARD OF SUPERVISORS AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

As the special resolution in relation to the cancellation of the Board of Supervisors and amendments to the Articles of Association has been duly passed at the EGM, the Company has canceled the Board of Supervisors with effect from October 24, 2025. The Audit Committee shall exercise the functions and powers of the Board of Supervisors as stipulated in the relevant laws and regulations and other regulatory documents.

The current members of the Board of Supervisors will cease to serve as Supervisors or hold any related positions in the Board of Supervisors, and the Rules of Procedure of the Board of Supervisors will be abolished. All members of the Board of Supervisors have confirmed that they have no disagreement with the Board and there are no other matters relating to the Company's cancellation of the Board of Supervisors that need to be brought to the attention of the Shareholders and/or the Stock Exchange.

The Board takes this opportunity to express its sincere gratitude to the Supervisors for their contributions to the Company during their tenure.

The amended Articles of Association shall take effect on October 24, 2025, and are published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.chinadzyl.com).

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

As the ordinary resolution in relation to the appointment of Mr. Xie Dong ("**Mr. Xie**") as an independent non-executive Director was duly passed at the EGM, Mr. Xie has been appointed as an independent non-executive Director of the fourth session of the Board with effect from October 24, 2025.

Concurrently, Ms. Wang Taosha ("**Ms. Wang**") has ceased to serve as an independent non-executive Director of the fourth session of the Board, a member of the Audit Committee and a member of the Nomination Committee with effect from October 24, 2025. Ms. Wang has confirmed that she has no disagreement with the Board and there are no other matters relating to her resignation that need to be brought to the attention of the Shareholders and/or the Stock Exchange.

Details of the biography of Mr. Xie and other information relating to his appointment were set out in the Circular. As of the date of this announcement, there has been no change to the biography of Mr. Xie and other information relating to his appointment.

Mr. Xie has confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that he has no past or present financial or other interest in the business of the Group and has no connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence in acting as an independent non-executive Director as at the date of this announcement.

The Board takes this opportunity to express its sincere gratitude to Ms. Wang for her contribution to the Company during her tenure and would like to extend its welcome to Mr. Xie for his new position.

ADJUSTMENT OF MEMBERS OF COMMITTEES UNDER THE BOARD

Reference is made to the announcement of the Company dated September 26, 2025, in relation to, among other things, adjustment of members of committees under the Board. From October 24, 2025, the member composition of the adjusted committees under the Board is set out as follows:

Audit Committee:

Chairman: Ms. Huang Suzhen
Members: Mr. Shu Yijie, Mr. Xie Dong

Nomination Committee:

Chairman: Mr. Yao Xue
Members: Mr. Shu Yijie, Ms. Huang Suzhen

The chairman and members of the Remuneration Committee remain unchanged.

ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR

Pursuant to the Company Law of the People's Republic of China (《中華人民共和國公司法》), and the amended Articles of Association, the Company shall appoint one employee representative Director following the cancellation of the Board of Supervisors.

At the employee representative meeting of the Company held on October 24, 2025, the employee representatives resolved to appoint Ms. Liu Hongchan (劉紅嬋) ("**Ms. Liu**") as the employee representative Director of the fourth session of the Board, with her term of office commencing on October 24, 2025 and ending on the date of expiration of the current session of the Board. Concurrently, Ms. Liu will continue to serve as an executive Director of the fourth session of the Board. Ms. Liu will not receive any remuneration for her appointment as an employee representative Director.

The biographical details of Ms. Liu are as follows:

Ms. Liu Hongchan (劉紅嬋), aged 51, joined our Group in November 2014 and was appointed as a vice general manager of our Company and the secretary to the Board in December 2014. Ms. Liu was appointed as a Director in October 2024 and is primarily responsible for the investment and procurement management, corporate governance and securities matters of our Group.

Ms. Liu has over 30 years of experience in finance management and corporate governance. Prior to joining our Group, she held various financial management positions in medical and healthcare industry. From July 1992 to July 1994, she served as the financial staff in Hubei Shashi Famen General Factory (湖北沙市閥門總廠). She then worked in Hubei Pharmaceutical Co., Ltd. (湖北省醫藥有限公司) from August 1994 to March 2005. Ms. Liu served as the financial manager in Hubei Wanjia Pharmaceutical Co., Ltd. (湖北萬佳醫藥有限公司) from April 2005 to November 2009. Subsequently, Ms. Liu served as the financial manager in Nanjing Pharmaceutical Hubei Co., Ltd. (南京醫藥湖北有限公司) from December 2009 to October 2014.

Ms. Liu obtained her associate diploma in finance management from Wuhan University (武漢大學) in July 1992 and her qualification certificate as an intermediate accountant (中級會計師) from Ministry of Finance of the PRC (中華人民共和國財政部) in May 2002.

Save as disclosed above, as at the date of this announcement, Ms. Liu (i) does not have any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any relationship with any Director, senior management or substantial or controlling Shareholders of the Company; (v) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vi) has no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to extend its welcome to Ms. Liu for her new position.

By order of the Board
Wuhan Dazhong Dental Medical Co., Ltd.
Mr. Yao Xue
Chairman and Executive Director

Wuhan, Hubei Province, PRC
October 24, 2025

As at the date of this announcement, the Board of the Company comprises: (i) Mr. Yao Xue, Ms. Shen Hongmin, Mr. Guo Jiaping and Ms. Liu Hongchan as executive Directors; and (ii) Mr. Shu Yijie, Ms. Huang Suzhen and Mr. Xie Dong as independent non-executive Directors.